Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock in a transaction on Monday, September 11th. The shares were sold at an average price of $65.00, for a total value of $975,000.00. Following the transaction, the insider now owns 6,264 shares of the company’s stock, valued at approximately $407,160. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Biller also recently made the following trade(s):

  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $61.99, for a total value of $133,030.54.
  • On Wednesday, August 2nd, Scott Biller sold 23,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $59.60, for a total value of $1,379,501.60.
  • On Friday, July 7th, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $55.00, for a total value of $118,030.00.
  • On Wednesday, June 21st, Scott Biller sold 4,292 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $55.00, for a total value of $236,060.00.

Shares of Agios Pharmaceuticals, Inc. (AGIO) opened at 66.43 on Friday. The company’s market cap is $3.21 billion. The company has a 50 day moving average price of $60.25 and a 200 day moving average price of $54.45. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the prior year, the company posted ($1.47) EPS. The business’s revenue for the quarter was up 62.1% on a year-over-year basis. Equities analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/16/agios-pharmaceuticals-inc-agio-insider-sells-975000-00-in-stock.html.

AGIO has been the subject of a number of research analyst reports. Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. Cann reissued a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Oppenheimer Holdings, Inc. set a $75.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 1st. Finally, BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $75.11.

A number of hedge funds have recently modified their holdings of AGIO. BlackRock Inc. raised its stake in Agios Pharmaceuticals by 8,463.5% in the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after acquiring an additional 2,141,768 shares during the last quarter. FMR LLC raised its stake in Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares during the last quarter. Vanguard Group Inc. raised its stake in Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth $20,423,000. Institutional investors own 94.30% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.